Hybrid Resin Composite Vs. Hybrid Ceramic Onlays for Restoring Carious Molars
Launched by PETER MEDHAT YOUSSEF GERGES · Feb 6, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different types of materials used to fix cavities in back teeth, called molars. The researchers want to see which material, a hybrid resin composite or a hybrid ceramic onlay, works better over time. They will also check how much each material wears down after 18 months. If you participate, you'll receive one of these materials for your molar and will have follow-up visits at 6, 12, and 18 months to check how well the restoration is holding up.
To be eligible for this trial, you should be between the ages of 18 and 62, able to handle dental procedures, and willing to commit to the follow-up appointments. However, if you have severe cavities or specific types of tooth damage, you might not qualify. This study is important because it aims to find the best option for treating tooth decay, helping both patients and dentists make informed choices about dental care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to tolerate necessary restorative procedures
- • Willing to sign the informed consent
- • Accepts the follow-up period
- Exclusion Criteria:
- • ICDAS 4/5 cavities in first and second permanent molars
- • Onlay cavities with at least one cusp coverage
- • Patients with acceptable oral hygiene
About Peter Medhat Youssef Gerges
Peter Medhat Youssef Gerges is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Mr. Gerges brings a wealth of experience in clinical trial management and regulatory compliance. His leadership emphasizes rigorous scientific methodology, ethical standards, and collaboration with healthcare professionals to ensure the successful execution of trials. By fostering partnerships with research institutions and stakeholders, he aims to contribute significantly to the development of safe and effective treatments across various medical disciplines.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported